To validate the performance of the MASE‐CE assay for detecting KRAS, NRAS, BRAF mutations and MSI status on clinical samples, we assessed the consistency of MASE‐CE and NGS for mutation detection or PCR‐CE for MSI detection in 190 patients with CRC. Here, BRAF is linked to colorectal carcinoma.